1stOncology™: Cancer Intelligence Service – Page 13770 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Alphamab Oncology Announces Completion of US$60 Million Series B Financing

On May 28, 2019 Alphamab Oncology, a leading biopharmaceutical company dedicated to global development of innovative biologics for cancer therapy, reported that it has completed a US$60 million Series B financing led by Hudson Bay Capital Management LP and participated by new investors including entrepreneur Adrian Cheng (Press release, Alphamab, MAY 28, 2019, View Source [SID1234536619]). Existing institutional investors including China Venture Capital Fund (CVC), PAG, and Advantech Capital also participated. Proceeds from the financing round will be used for developing the pipeline, commissioning a new R&D and manufacturing site, accelerating the clinical development of clinical stage assets, and preparing for commercial launch of KN035 (Envafolimab).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Alphamab Oncology is well positioned to develop next-generation multi-functional biologics therapy for cancer treatment based on its extensive expertise in protein engineering and proprietary platforms including Bispecific and Mix-mAb Platforms as well as rich experience in single domain antibodies. The company has also assembled highly experienced management and technical teams with experiences covering the entire R&D process of innovative biologic drugs.

The new round comes on the heel of its strong US$130 million Series A financing in November 2018 – one of the largest in China’s biotechnology industry in recent years. Since then, Alphamab Oncology has advanced several drug candidates in its pipeline and formed new partnerships for its leading assets:

KN035 (Envafolimab), the world’s leading subcutaneous injection of PD-L1 antibody, entered phase II and phase III clinical trials for multiple indications.
KN046, the world’s first PD-L1/CTLA-4 bispecific antibody, has undergone phase I clinical trials in Australia and China which has demonstrated promising early clinical results, and is undergoing phase II clinical trials for multiple indications in China. Additionally, Alphamab Oncology reached a partnership with HEC Research Institute and TOT Biopharm to develop innovative combination therapies involving KN046.
KN026, an anti-HER2 bispecific antibody, is starting phase II clinical trial in China.
Immunomodulator KN019 is undergoing phase II clinical trial in China.
"Since the founding of the company, we have been working hard to break new grounds. We have been focusing on the development of key platforms and proprietary innovative drug candidates, and consistently executing our long-term strategy, focusing on global development for innovative biological dugs. We are striving to transform cancer into a controllable and treatable disease and to improve quality of life of cancer patients," said Dr. Ting Xu, Founder, Chairman and CEO of Alphamab Oncology. "We are very grateful to these prestigious investors for their enthusiasm and confidence in Alphamab Oncology. We look forward to working with our stakeholders to accelerate the new generation of multi-functional biological therapeutics, and to fulfill our vision to be globally competitive."

Sander Gerber, Chief Executive Officer and Chief Investment Officer of Hudson Bay Capital Management LP, added, "We are pleased to support Alphamab Oncology in its mission of creating effective, high quality and affordable biotherapeutics for cancer treatment. Hudson Bay’s investment in Alphamab Oncology underscores our confidence in the company’s ability to be a next-generation leader in the development and commercialization of innovative biological oncology drugs globally. We look forward to helping Alphamab Oncology advance its strong product pipeline to drive significant value for the business over time."

Mr. Shaojing Ma, Managing Director of China Venture Capital Fund (CVC) commented: "Alphamab Oncology leads the new-generation innovative biopharmaceutical industry in China. As a Series A shareholder, China Venture Capital Fund is excited to witness that, within one year, the Company has achieved rapid progress in R&D and clinical development, and various data has proven the tremendous growth potential of its products; with a more robust product pipeline, the Company has demonstrated its capability to maintain world-leading R&D of innovative drugs. Therefore, we are also actively participating in this Series B funding. We expect that after entering the capital market in the future, Alphamab Oncology will gain more opportunities for international development and stands out as an excellent representative of innovative Chinese biopharmaceutical companies to the world."

Adrian Cheng commented: "Technological innovation can be a powerful tool in improving the human condition. I believe that advances in biotechnology and pharmaceuticals will be crucial in changing our lives for the better, and I am delighted to see China taking its place at the forefront of medical innovation. Alphamab Oncology boasts world-class capabilities in ground-breaking research and development and they’re very strong in team execution. We are pleased to be a contributor to Alphamab Oncology’s growth as it becomes the world’s leading research and development company for tumor-targeted drugs."

Biocept Awarded Patent in China for its Circulating Tumor Cell Platform Expanding Intellectual Property Estate to 33 Issued Patents Globally

On May 28, 2019 Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, reported that it has been awarded Chinese Patent No. ZL201080019566.9 entitled, DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS (Press release, Biocept, MAY 28, 2019, View Source [SID1234536618]). The issued patent covers methods and devices for the capture of rare cells of interest, including CTCs that are shed into the blood stream by solid tumors where an antibody, or mixture of antibodies, and a microchannel are used for cell capture, detection, and analysis. The patent encompasses the use of any biological sample type of interest and is the 33rd patent issued to Biocept that is core to its liquid biopsy technology and commercial testing platforms.

"The granting of this patent further expands Biocept’s international footprint for capturing and analyzing rare cells from biological fluids, such as blood, bone marrow, cerebral spinal fluid (CSF), and tissue, to assess the status of patients with cancer," said Lyle Arnold, Ph.D., Chief Scientific Officer at Biocept. "This technology interfaces well with Biocept’s other patented liquid biopsy technologies that include a blood collect tube and circulating tumor DNA (ctDNA) analysis, which are intended to aid physicians in the treatment of their patients with cancer."

"Obtaining this new patent provides additional intellectual property coverage for the unique and novel features of our Target Selector platform, featuring our antibody cocktail and microchannel capture technologies for CTCs and other rare cells of interest," said Michael Nall, Biocept’s President and CEO. "We believe that the issuance of additional patents around the world leverages our investment in our cutting-edge liquid biopsy technologies and expands the opportunity for Biocept to generate revenue in territories outside the U.S."

CELLSEARCH Studies at ASCO Show Potential Predictive Role for Circulating Tumor Cells in Metastatic Breast Cancer

On May 28, 2019 Menarini Silicon Biosystems, the pioneer of liquid biopsy and single cell technologies, reported that two studies using the company’s CELLSEARCH Circulating Tumor Cell (CTC) test provided preliminary insight into the impact of liquid biopsy on metastases and prognosis for patients with metastatic breast cancer (MBC) (Press release, Menarini, MAY 28, 2019, View Source [SID1234536617]). The studies involving CELLSEARCH, considered the gold standard in liquid biopsy technology, will be presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper).

In both studies, researchers from Northwestern University used the FDA-cleared CELLSEARCH system to isolate CTCs in the same population of 85 MBC patients. In the first study, they explored the role of CTCs and circulating tumor DNA (ctDNA) in predicting metastatic sites. Researchers found that mutations in ESR1 were associated with liver metastases. In addition, patients with both hormone receptor-positive MBC and ESR1 mutations also had bone metastases, as did patients with high CTC counts (≥ 5 CTCs/7.5 mL blood).

"We currently do not have any biomarker to predict where metastases will occur. As a result, every patient with metastatic breast cancer receives the same monitoring and treatments even though we know some patients with specific sites of recurrence may be more resistant to some specific interventions," said study coauthor Massimo Cristofanilli, M.D., F.A.C.P., Associate Director of Translational Research at the Robert H. Lurie Medical Research Center, Northwestern University. "These results are quite intriguing, and we should continue to investigate whether patients with certain mutations or CTC characteristics that appear to be more prone to develop visceral metastasis can be better directed to more tailored imaging monitoring and personalized targeted therapies."

In the second study, researchers analyzed isolated CTCs and cell-free DNA (cfDNA) from the same patient population to investigate the impact of biological tumor characteristics on prognosis. They found that patients whose cfDNA harbored ESR1 mutations and HER2 alterations had a higher number of CTCs and higher average number of metastatic sites than patients whose cfDNA did not. Patients with both mutations in ESR1 and alterations in HER2 had the worst overall survival.

"While these results are preliminary, we hope to verify that this combination of ESR1 mutations and HER2 alterations results in more aggressive MBC," said study coauthor Lorenzo Gerratana, M.D., a research fellow in medical oncology with the Robert H. Lurie Medical Research Center, Northwestern University and University of Udine, Italy. "In the future, this could potentially expand the role of liquid biopsy for enumerating CTCs and monitoring metastatic prognosis."

CELLSEARCH is the first and only clinically validated blood test cleared by the FDA for detecting and enumerating CTCs to aid physicians in managing patients with metastatic breast, prostate, and colorectal cancers* when used in conjunction with other clinical methods of monitoring. The test is also approved by the China Food & Drug Administration for use in monitoring patients with MBC.

"There is already a large body of research showing that the CELLSEARCH CTC test provides clinically actionable information," said Fabio Piazzalunga, President and CEO of Menarini Silicon Biosystems, Inc. "While still exploratory, these studies represent another important step in advancing precision medicine for metastatic breast cancer."

The CELLSEARCH System is the most extensively studied CTC technology, with research published in more than 650 peer-reviewed publications. Providing valuable information to help physicians make patient-management decisions along with other clinical monitoring methods, the CELLSEARCH CTC test is performed at a reference laboratory using the CELLSEARCH System. CELLSEARCH CTC testing can be used throughout a given therapy for metastatic breast, colorectal, and prostate cancer to monitor a patient’s status by showing if their prognosis is favorable.

To learn more about the CELLSEARCH System, ASCO (Free ASCO Whitepaper) annual meeting attendees can visit Menarini Silicon Biosystems at Booth #4111.

POSTER PRESENTATION: Can the enumeration of circulating tumor cells (CTCs) and the characterization of circulating tumor DNA (ctDNA) provide insight into organ tropism in metastatic breast cancer? (Abstract #3038)
Lead Author: Lorenzo Gerratana, M.D.; Department of Medicine, University of Udine
Session Title: Developmental Therapeutics and Tumor Biology (Nonimmuno)
Date: Saturday, June 1, 2019
Time: 8:00 am – 11:00 am
Location: Hall A
Poster Board #30

POSTER PRESENTATION: Association of HER2 alterations and ESR1 mutations in cell-free DNA (cfDNA) with circulating tumor cells (CTCs), multiple metastasis, and prognosis in stage III/IV breast cancer (BCa) (Abstract #1036)
Lead Author: Qiang Zhang, M.D., Ph.D.; Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Session Title: Breast Cancer – Metastatic
Date: Sunday, June 2, 2019
Time: 8:00 am – 11:00 am
Location: Hall A
Poster Board #117

ORIC Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference

On May 28, 2019 ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance, reported that Jacob Chacko, MD, Chief Executive Officer, will present and host one-on-one investor meetings at the Jefferies 2019 Global Healthcare Conference held June 4-7th at the Grand Hyatt in New York (Press release, ORIC Pharmaceuticals, MAY 28, 2019, View Source [SID1234536616]). Dr. Chacko will present on Thursday, June 6th at 8:30am ET.

IDEAYA Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

On May 28, 2019 IDEAYA Biosciences, Inc. (Nasdaq:IDYA) reported the closing of its initial public offering of 5,750,000 shares of common stock at a public offering price of $10.00 per share (Press release, Ideaya Biosciences, MAY 28, 2019, View Source [SID1234536615]). The gross proceeds from the offering were $57.5 million before deducting underwriting discounts, commissions and estimated offering expenses. This includes the exercise in full by the underwriters of their option to purchase up to 750,000 additional shares of common stock from the company at the public offering price, less underwriting discounts and commissions. All of the shares of common stock were offered by IDEAYA Biosciences. The shares commenced trading on the Nasdaq Global Select Market on May 23, 2019, under the ticker symbol "IDYA".

J.P. Morgan, Citigroup and Jefferies acted as joint book-running managers for the offering.

A registration statement relating to the shares being sold in this offering was declared effective by the Securities and Exchange Commission on May 22, 2019. The offering is being made only by means of a prospectus, copies of which may be obtained from: J.P. Morgan, by mail at J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 866-803-9204, or by email at [email protected]; Citigroup, by mail at Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 1-800-831-9146; or Jefferies, by mail at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at 877-547-6340 or 877-821-7388, or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.